DSM-Firmenich Elects Richard Ridinger as Chairman
The leadership change at the global firm may signal shifts in oversight for the company's 21,000 employees and operations.
Updated on Oct. 21, 2026 in People
Live Poll
Do you trust that new corporate board leadership will improve a company's long-term performance?
Shareholders of DSM-Firmenich have elected Richard Ridinger as the new chairman of the board of directors. This leadership transition took place at an extraordinary general meeting on October 19, with Ridinger succeeding Thomas Leysen in the role.
Why it matters
For operators managing large-scale global enterprises, board turnover at major entities like DSM-Firmenich often signals shifts in oversight strategy or focus. Ridinger brings extensive experience from his previous leadership roles in the life sciences sector.
DSM-Firmenich currently operates in nearly 60 countries and generates annual revenue exceeding €9 billion from its continuing operations. The group supports this footprint with a global workforce of approximately 21,000 employees.
The players
Richard Ridinger
The new chairman of DSM-Firmenich who previously served as the leader of Lonza from 2012 to 2019.
DSM-Firmenich
A global company listed on Euronext Amsterdam and the SIX Swiss Exchange that operates in nearly 60 countries.
Thomas Leysen
The outgoing chairman of the board of directors at DSM-Firmenich who stepped down from his position.
The details
Ridinger, who has served as an independent director at the company since 2023, was confirmed for the chairmanship during an extraordinary general meeting. He brings 30 years of life sciences experience to the position, including a seven-year tenure leading Lonza from 2012 to 2019. In addition to his board responsibilities, he joins the firm's remuneration committee, signaling his direct involvement in executive compensation and talent strategy.
Timeline
2012-2019: Richard Ridinger led Lonza.
2016-2023: Richard Ridinger served on the Firmenich board of directors.
2023: Ridinger began his term as an independent director.
August 18, 2026: Company first announced the appointment.
October 19, 2026: Shareholders confirmed the appointment at an extraordinary general meeting.
Market Landscape
This leadership transition marks a significant governance evolution for the entity established by the 2023 merger forming DSM-Firmenich. The appointment of an experienced life sciences executive reflects the company's focus on maintaining stability as a publicly traded group.
Operators should monitor upcoming regulatory filings and investor communications for shifts in long-term capital allocation or operational strategy. Changes at the board level often precede adjustments to internal compensation structures and hiring priorities.
The takeaway
The election of a veteran leader to the board suggests a focus on institutional continuity and deep industry expertise. Managers should track board disclosures for changes in committee oversight, as these shifts often serve as early indicators of long-term strategic recalibrations.
Further reading
For more on how shifts in corporate leadership influence organizational direction, visit our People section.
Live Poll
Do you trust that new corporate board leadership will improve a company's long-term performance?
